A spotlight on schizophrenia at the upcoming APA 2022 Annual Meeting
The American Psychiatric Association (APA) 2022 Annual Meeting will be held in-person, with a virtual four-day meeting following the live event. Attendees will be gathering in New Orleans, a city world renowned for its jazz music and Creole cuisine, on May 21–25. APA 2022 offers a place to connect with colleagues and get up-to-date with the latest scientific advances. This article outlines the events of interest taking place at this year’s APA meeting that focus on schizophrenia.
Click here for more information on APA
Key symposia:
How the social determinants of mental health relate to neuropsychiatric disorders, and what we can do about them in clinical practice
Saturday 21 May | 3:00 PM – 4:00 PM CDT | Product Showcase #2 (Booth 3414)
“The social determinants of health are the non-medical factors that influence health outcomes”.1 Social determinants of mental health can include discrimination, social isolation, and stigma.2 In this interactive symposium, Michael Compton, Cynthia Armand, and Craig Chepke will discuss why the social determinants of mental health are relevant to neuropsychiatric disorders, including schizophrenia. They will also outline how clinicians can tackle the healthcare barriers faced by patients, and how the mental health consequences of neuropsychiatric disorders can be addressed.
Join the conversation on Twitter!
#TevaAPA_SDMH
#TevaCNS
#APAAM22
Long-acting injectables in schizophrenia: dispelling myths, unlocking clinical value
Monday 23 May | 2:00 PM – 3:00 PM CT | Product Showcase #2 (Booth 3414)
Three of the persistent myths about long-acting injectables (LAIs) in schizophrenia are that:
1. Clinicians know when patients are nonadherent
2. Patients do not want LAI treatment
3. LAIs are only appropriate for nonadherent patients
In this symposium, these myths will be dispelled by presenters John Kane, Leslie Citrome, Christoph Correll, and Jose Rubio. The presentations will be followed by a discussion of the potential role of LAIs in addressing clinical dilemmas in schizophrenia.
Join the conversation on Twitter!
#APA_SCOPE
#APA_LAImyths
#APAAM22
Key oral presentations :
- The Accelerating Medicines Partnership in Schizophrenia®: Big data for psychosis prediction. 05.21.2022, 10:30 AM–12:00 PM (CDT). Rooms 383–385, Ernest N. Morial Convention Center. Scott Woods, Patrick McGorry, and Rene Kahn will provide an overview of the Accelerating Medicines Partnership in Schizophrenia® initiative, an international research network focused on developing predictive biomarkers for psychosis.
- A circuits-first approach to mental illness: Development of precision medicines for the brain. 05.21.2022, 1:30 PM–3:00 PM (CDT). Room 288, Ernest N. Morial Convention Center. Amit Etkin will discuss findings from research of neural circuit signatures that suggest that scalable and clinically applied innovations may soon be available for the diagnosis and treatment of mental illness.
- The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia. 05.22.2022, 10:30 AM–12:00 PM (CDT). Room 293, Ernest N. Morial Convention Center. Joseph Thomas Coyle will describe the limitations of the dopamine hypothesis, and discuss recent research that implicates glutamatergic neurotransmission, particularly at the N-methyl-D-aspartate (NMDA) receptor, in the pathophysiology of schizophrenia.
- The biological underpinnings of schizophrenia: From the genome to the connectome. 05.23.2022, 10:30 AM–12:00 PM (CDT). Rooms 271–273, Ernest N. Morial Convention Center. Anil Malhotra will begin this presentation by reviewing the symptoms, prevalence, risk factors, and treatment of schizophrenia. He will then discuss new findings from genetic and imaging-based research that provide new clues to schizophrenia pathophysiology.
- Early-stage investigators and timely support: The OPAL Center and its mission to fund and train the next generation of schizophrenia researchers. 05.25.2022, 1:30 PM–3:00 PM (CDT). Room 296, Ernest N. Morial Convention Center OPAL (Optimizing and Personalizing interventions for people with schizophrenia Across the Lifespan) is a center specifically focused on the needs of people diagnosed with schizophrenia. Stephanie Alexia Rolin, Ana Stefancic, and Natalie Bareis will present the goals of OPAL, followed by a discussion of the unmet needs of people with schizophrenia and findings from recent OPAL studies
Teva Medical Affairs booth (#1533)
The Teva Medical Affairs booth will be accessible throughout the congress, providing a wealth of educational resources and an opportunity to speak with members of the Teva team. Teva will also be hosting Meet-the-Expert sessions in the seating area of the Medical Affairs booth, with the following three expert speakers from the two Teva-sponsored sessions available as follows:
- Leslie Citrome, MD
- Sunday, May 22: 3:00–4:00 PM (CDT)
- Christoph Correll, MD (attending virtually)
- Sunday, May 22: 1:00–1:30 PM (CDT)
- Monday, May 23: 3:30–4:00 PM (CDT)
- Craig Chepke, MD
- Saturday, May 21: 4:30–5:00 PM (CDT)
- Monday, May 23: 9:30–10:00 AM (CDT)
The booth will also showcase a suite of materials on the utilization of motivational interviewing to encourage positive clinical outcomes in patients with schizophrenia, including videos and an interactive activity. A number of take-home pieces, including infographics on schizophrenia and social determinants of neuropsychiatric disorders, will also be available.
Click here to learn more about motivational interviewing
Click here to view a webinar on schizophrenia and long-acting injectables
World Health Organization. Social determinants of health. 2022. Available at: https://www.who.int/health-topics/social-determinants-of-health#tab=tab_1 (last accessed 21 April 2022)
World Health Organization. Social determinants of mental health. 2014. Available at: https://apps.who.int/iris/bitstream/handle/10665/112828/9789241506809_eng.pdf (last accessed 21 April 2022)
